No Cover Image

Journal article 11 views

Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results

Indranil Dasgupta, Aghogho Odudu, Jyoti Baharani, Niall Fergusson, Helen Griffiths, John Harrison, Awais Hameed, Paul Maruff, Louise Ryan, Neil Thomas, Gavin Woodhall, George Tadros

BMC Nephrology, Volume: 25, Start page: 466

Swansea University Author: Helen Griffiths

Full text not available from this repository: check for access using links below.

Abstract

Background: Cognitive impairment is common in haemodialysis patients with no known beneficial interventions. Cooler dialysate slows brain white-matter changes, but its effect on cognition is unknown. This feasibility trial was performed to inform a fully-powered, randomised trial to assess this. Met...

Full description

Published in: BMC Nephrology
ISSN: 1471-2369
Published: Springer Nature 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa68613
Abstract: Background: Cognitive impairment is common in haemodialysis patients with no known beneficial interventions. Cooler dialysate slows brain white-matter changes, but its effect on cognition is unknown. This feasibility trial was performed to inform a fully-powered, randomised trial to assess this. Methods: We aimed to randomise (1:1) 90 haemodialysis patients to this double-blinded, randomised controlled feasibility trial to standard care (dialysate-temperature 36.5 °C) or intervention (35 °C). Eligible patients were adult chronic haemodialysis recipients with no established diagnosis of dementia or psychiatric disease. The primary outcome was change in Montreal Cognitive Assessment (MoCA) score at 12-months. Secondary outcomes included recruitment and attrition rates, reasons for non-recruitment, intradialytic hypotension, depression, patient burden, computerised cognition test battery, and quality of life. Findings: Of 334 patients screened, 160 were eligible. 99 declined mainly for the extra non-dialysis day study visits. Sixty-one patients consented, 43 randomised – 20 in standard care, 23 in intervention arms; 13 withdrew for non-dialysis day visits and 5 without reason before randomisation. 27 patients (12 standard care, 15 intervention) completed the trial – 5 died, 1 transplanted, 4 withdrew consent, and 6 could not attend due to the pandemic. Low temperature dialysis was well tolerated. There was no difference in change in MoCA from baseline to 12 months between the standard and intervention arms; 1.0 (-2.8–3.0, p = 0.755) and − 2.0 (-1.0 - -4.0, p = 0.047) respectively. There were no differences between groups on any secondary measures. There were no significant adverse events reported. Discussion: The trial was significantly affected by the COVID-19 pandemic contributing to an attrition rate of 27%. The non-dialysis day research visits were mainly responsible for low recruitment and consent withdrawal. There are several learning points, described in the article, which will inform design of definitive trials in this area in the future. Trial registration: ClinicalTrials.gov Identifier NCT03645733. Registration date 24/08/2018.
Keywords: Cognition, Cooled dialysate, Feasibility trial, Haemodialysis, Randomised controlled trial
College: Faculty of Medicine, Health and Life Sciences
Funders: The study is funded by a National Institute for Health Research (NIHR) for Patients Benefit grant (PB-PG-1215-20008). The study is also supported by the NIHR Clinical Research Network West Midlands, UK.
Start Page: 466